Table 6.
Comparison between the patients with HCC and those without HCC in the 137 patients without past history of IFN treatment
| Patients with HCC | Patients without HCC | Comparison between patients with HCC and those without HCC | Multiple regression analysis for factors associated with HCC development | ||
|---|---|---|---|---|---|
| (n = 31) | (n = 106) | Odds ratio (95% confidence interval) | p | ||
| Age (yrs) | 70.9±7.1 | 62.3±11.9 | P = 0.0002 | 1.09 (1.04 - 1.15) | p = 0.0006 |
| Gender (male/female) | 16/15 | 48/58 | NS | NS | |
| BMI (kg/m2) | 23.1±4.0 | 21.9±3.4 | NS | ||
| PNPLA3 (GG/CC・CG) | 8/23 | 14/92 | P = 0.0928 | NS | |
| AST (IU/L) | 80.7±64.3 | 51.4±41.8 | P = 0.0032 | ||
| ALT (IU/L) | 65.5±50.0 | 63.9±84.1 | NS | ||
| γ-GTP (IU/L) | 53.5±40.7 | 60.0±73.6 | NS | ||
| Albumin (g/dL) | 3.4±0.56 | 4.2±0.5 | p < 0.0001 | ||
| Total bilirubin (mg/dL) | 1.5±1.1 | 0.8±0.4 | p < 0.0001 | ||
| Platelet count (x104/μL) | 9.2±4.3 | 14.1±5.5 | P = 0.0008 | ||
| Prothrombin time (%) | 81.5±14.0 | 96.0±19.7 | P= 0.0002 | ||
| Hyaluronic acid (ng/mL) | 507.0±542.5 | 202.1±313.7 | P = 0.0002 | ||
| α-fetoprotein (ng/mL) | 475.9±1411.2 | 28.7±148.1 | P = 0.0016 | ||
| PIVKA-II(mAU/mL) | 47.0±51.0 | 20.8±10.7 | p < 0.0001 | ||
| HCV genotype (1/2/3) | 27/4/0 | 82/23/1 | NS | ||
| HCV RNA (log IU/mL) | 5.9±1.0 | 6.2±0.9 | NS | ||
| Velocity of shear wave (m/s) | 2.20±0.70 | 1.55±0.50 | p < 0.0001 | ||
HCC, hepatocellular carcinoma; IFN, interferon; BMI, body mass index; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II; NS, not significant.